Julie S. Cohen

Julie S. Cohen

Auto-generated profile, based on publicly available information

Julie S. Cohen

Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJSheng Chih Jin
Sheng Chih Jin
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
XZXue Zeng
Xue Zeng
MSMichael C. Sierant
Michael C. Sierant
MKMichael C. Kruer
Michael C. Kruer

14 October 2018 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
NNNancy Niguidula
Nancy Niguidula
CAChristina Alamillo
Christina Alamillo
LMLayla Shahmirzadi Mowlavi
Layla Shahmirzadi Mowlavi
ZPZöe Powis
Zöe Powis
JCJulie S. Cohen
Julie S. Cohen
KHKelly D. Farwell Hagman
Kelly D. Farwell Hagman
Background: Clinical diagnostic whole‐exome sequencing (WES) is a powerful tool for patients with undiagnosed genetic disorders. To demonstrate the clinical utility, we surveyed healthcare providers (HCP) about changes in medical management and treatment, diagnostic testing, reproductive planning, and use of educational services subsequent to WES testing.Methods: For a period of 18 months, an 18‐question survey was sent to HCPs attached to the WES reports. We analyzed the molecular diagnosis, patient clinical features, and the medical management changes reported in the returned surveys.Results: A total of 62 (2.2% of 2,876) surveys were returned, consisting of 37.1% patients with a positive or likely positive pathogenic alteration, 51.6% negative results, 9.7% uncertain findings, and 1 patient (1.6%) with a novel candidate finding. Overall, 100% of the HCPs of patients with positive or likely positive WES results (n = 23) and HCPs of patients with uncertain WES results (n = 6) responded positively to one of the 18 queries. Of note, 37.5% of the HCPs of patients with negative WES results (n = 32) responded positively to at least one query.Conclusion: Overall, these data clearly demonstrate the clinical utility of WES by demonstrating the impact on medical management irrespective of the exome result.

9 September 2022 in Genetics in Medicine
Verified
Journal Article
Open access
SKSayaka Kayumi
Sayaka Kayumi
LPLuis A. Pérez-Jurado
Luis A. Pérez-Jurado
MPMaría Palomares
María Palomares
SRSneha Rangu
Sneha Rangu
SSSarah E. Sheppard
Sarah E. Sheppard
MCMark Corbett
Mark Corbett
Germline loss-of-function variants in CTNNB1 cause neurodevelopmental disorder with spastic diplegia and visual defects (NEDSDV; OMIM 615075) and are the most frequent, recurrent monogenic cause of cerebral palsy (CP). We investigated the range of clinical phenotypes owing to disruptions of CTNNB1 to determine the association between NEDSDV and CP. Genetic information from 404 individuals with collectively 392 pathogenic CTNNB1 variants were ascertained for the study. From these, detailed phenotypes for 52 previously unpublished individuals were collected and combined with 68 previously published individuals with comparable clinical information. The functional effects of selected CTNNB1 missense variants were assessed using TOPFlash assay. The phenotypes associated with pathogenic CTNNB1 variants were similar. A diagnosis of CP was not significantly associated with any set of traits that defined a specific phenotypic subgroup, indicating that CP is not additional to NEDSDV. Two CTNNB1 missense variants were dominant negative regulators of WNT signaling, highlighting the utility of the TOPFlash assay to functionally assess variants. NEDSDV is a clinically homogeneous disorder irrespective of initial clinical diagnoses, including CP, or entry points for genetic testing.

11 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKMarija Kojic
Marija Kojic
TGTomasz Gawda
Tomasz Gawda
MGMonika Gaik
Monika Gaik
ABAlexander Begg
Alexander Begg
ASAnna Salerno-Kochan
Anna Salerno-Kochan
BWBrandon J. Wainwright
Brandon J. Wainwright
Intellectual disability (ID) and autism spectrum disorder (ASD) are the most common neurodevelopmental disorders and are characterized by substantial impairment in intellectual and adaptive functioning, with their genetic and molecular basis remaining largely unknown. Here, we identify biallelic variants in the gene encoding one of the Elongator complex subunits, ELP2, in patients with ID and ASD. Modelling the variants in mice recapitulates the patient features, with brain imaging and tractography analysis revealing microcephaly, loss of white matter tract integrity and an aberrant functional connectome. We show that the Elp2 mutations negatively impact the activity of the complex and its function in translation via tRNA modification. Further, we elucidate that the mutations perturb protein homeostasis leading to impaired neurogenesis, myelin loss and neurodegeneration. Collectively, our data demonstrate an unexpected role for tRNA modification in the pathogenesis of monogenic ID and ASD and define Elp2 as a key regulator of brain development.

28 August 2024 in Human Genetics and Genomics Advances
Verified
Journal Article
Open access
GCGiovanna Carpentieri
Giovanna Carpentieri
SCSerena Cecchetti
Serena Cecchetti
Gianfranco BocchinfusoGianfranco Bocchinfuso
Gianfranco Bocchinfuso
FRFrancesca Clementina Radio
Francesca Clementina Radio
CLchiara leoni
chiara leoni
EFElisabetta Flex
Elisabetta Flex
The vacuolar H+-ATPase (V-ATPase) is a functionally conserved multimeric complex localized at the membranes of many organelles where its proton-pumping action is required for proper lumen acidification. The V-ATPase complex is composed of several subunits, some of which have been linked to human disease. We and others previously reported pathogenic dominantly acting variants in ATP6V1B2, the gene encoding the V1B2 subunit, as underlying a clinically variable phenotypic spectrum including dominant deafness-onychodystrophy (DDOD) syndrome, Zimmermann-Laband syndrome (ZLS), and deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures (DOORS) syndrome. Here, we report on an individual with features fitting DOORS syndrome caused by dysregulated ATP6V1C1 function, expand the clinical features associated with ATP6V1B2 pathogenic variants, and provide evidence that these ATP6V1C1/ATP6V1B2 amino acid substitutions result in a gain-of-function mechanism upregulating V-ATPase function that drives increased lysosomal acidification. We demonstrate a disruptive effect of these ATP6V1B2/ATP6V1C1 variants on lysosomal morphology, localization, and function, resulting in a defective autophagic flux and accumulation of lysosomal substrates. We also show that the upregulated V-ATPase function affects cilium biogenesis, further documenting pleiotropy. This work identifies ATP6V1C1 as a new gene associated with a neurodevelopmental phenotype resembling DOORS syndrome, documents the occurrence of a phenotypic continuum between ZLS, and DDOD and DOORS syndromes, and classify these conditions as lysosomal disorders.

6 February 2020 in Journal of Genetic Counseling
Verified
Journal Article
Open access
PDF file
ANAhna Neustadt
Ahna Neustadt
JOJill Owczarzak
Jill Owczarzak
WMWeiyi Mu
Weiyi Mu
JCJulie S. Cohen
Julie S. Cohen
LELori Erby
Lori Erby
Patients pursuing exome sequencing (ES) in their quest for diagnosis will most often experience unresolved uncertainty from their ES results because the majority of ES results are non‐diagnostic. This study explored and compared the experiences of receiving two types of ES results that may result in diagnostic uncertainty. Semi‐structured phone interviews were conducted with 23 adult patients with undiagnosed conditions who received either a negative result or a result with one or more variants of uncertain significance (VUSs) from ES. Interviews were transcribed and subjected to thematic and comparative analyses. Participants accurately understood their results and described various sources of genomic uncertainty including probability, complexity, and ambiguity. Their acclimation to illness uncertainty resulted in realistic expectations about and acceptance of their results. Participants still hoped that ES would end their diagnostic odyssey. Hope and optimism were used to cope with continued uncertainty. No thematic differences were found between the experiences of those who received negative results versus those who received VUSs. Our findings may inform clinical practices of informed consent and disclosure of negative results and VUSs through a greater consideration of patients' reactions, concerns, and challenges with adaptation to uncertainty.